CG
NWBO

Cutler Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Cutler Group’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-463
Closed – – 8080
2016
Q3 		$0 Sell
463
-26,796
-98% -$12.3K ﹤0.01% 8079
2016
Q2 		$15K Buy
27,259
+1,807
+7% +$1.93K ﹤0.01% 3723
2016
Q1 		$37K Buy
25,452
+16,552
+186% +$32.7K ﹤0.01% 2657
2015
Q4 		$28K Buy
+8,900
New +$42.8K ﹤0.01% 3091

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Cutler Group's NWBO Position: Q4 2016 in Review

Cutler Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 463 shares.

Cutler Group first reported a position in NWBO in Q4 2015 and held it in 4 quarters. The position peaked at $37K in Q1 2016. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Cutler Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Cutler Group sold 463 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016.
  • Cutler Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2015 and held it in 4 quarters.
  • Cutler Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $37K in Q1 2016.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Cutler Group's 13F filing for Q4 2016, filed 12 Jan 2017.